Paratek Pharmaceuticals, Inc. (PRTK)

1.8600 +0.4900 (+35.77%) At close: 04:00PM EDT

Paratek Pharmaceuticals, Inc.

75 Park Plaza
4th Floor
Boston, MA 02116
United States
617 807 6600
https://paratekpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 207

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA	Exec. Chairman	934.7k	N/A	1958
Dr. Evan Loh FACC, FAHA, M.D.	CEO & Director	1.07M	N/A	1959
Mr. Adam Woodrow	Pres & Chief Commercial Officer	735.48k	N/A	1967
Ms. Sarah Higgins	VP of Fin., Controller & Principal Accounting Officer	N/A	N/A	1975
Mr. Jason Burdette	Sr. VP of Technical Operations	N/A	N/A	N/A
Mr. Ben Strain	VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO	N/A	N/A	N/A
Mr. William M. Haskel	Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer	N/A	N/A	1962
Ms. Karen McGrath	Sr. VP of HR	N/A	N/A	N/A
Mr. Randall B. Brenner	Chief Devel. & Regulatory Officer	N/A	N/A	1973

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Corporate governance

Paratek Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 February 2023 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.